HIV microbicides: Where are we now?

Current HIV Research

Volumn 10, Issue 1, 2012, Pages 1-2

  Quiñones Mateu, Miguel E ^a   Vanham, Guido ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Antiretroviral therapy; HIV; Microbicide; Prevention; Transmission

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE; MICROBICIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

CIRCUMCISION; CONDOM; DRUG SAFETY; EDITORIAL; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE HOMOSEXUAL; MONOTHERAPY; NONHUMAN; PREVENTIVE MEDICINE; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS, LOCAL; ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS;

EID: 84857128726     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212799304724     Document Type: Editorial

References (15)

1. Balzarini J, Pauwels R, Herdewijn P, et al. Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'- unsaturated derivative of 2',3'-dideoxycytidine. Biochem Biophys Res Commun 1986; 140(2): 735-742.
2. Hirsch MS, Kaplan JC. Prospects of therapy for infections with human T-lymphotropic virus type III. Annals of internal medicine 1985; 103(5): 750-755.
3. Fischinger PJ, Robey WG, Koprowski H, Gallo RC, Bolognesi DP. Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III). Cancer Res 1985; 45(9 Suppl): 4694s-4699s.
4. Beardsley T. AIDS progress. Synthetic vaccine only a distant prospect. Nature 1985; 314(6013): 659.
5. Lange JM, Karam M, Piot P. Boost for vaginal microbicides against HIV. Lancet 1993; 342(8883): 1356.
6. Bourinbaiar AS, Fruhstorfer EC. The efficacy of nonoxynol-9 from an in vitro point of view. Aids 1996; 10(5): 558-559.
7. Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998; 339(8): 504-510.
8. van De Wijgert J, Fullem A, Kelly C, et al. Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr 2001; 26(1): 21-27.
9. Arien K, Jespers V, Vanham G. HIV sexual transmission and microbicides. Rev Med Virol 2011; 21: 110-133.
10. Pirrone V, Thakkar N, Jacobson JM, Wigdahl B, Krebs FC. Combinatorial approaches to the prevention and treatment of HIV- 1 infection. Antimicrob Agents Chemother 2011; 55(5): 1831-1842.
11. Hladik F, Doncel GF. Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res 2010; 88 Suppl 1: S3-S9.
12. McGowan I. Rectal microbicides: can we make them and will people use them? AIDS Behav 2011; 15 Suppl 1: S66-S71.
13. Abdool KQ, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science [science.1193748 pii 0.1126/science.1193748 doi] 2010; 329(5996): 1168-1174.
14. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363(27): 2587-2599.
15. Stephenson J. Study halted: no benefit seen from antiretroviral pill in preventing HIV in women. JAMA 2011; 305(19): 1952.